Moderna Stock In The News

Moderna stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Moderna earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
There is far too much social signal, news, headlines, and media speculation about Moderna that is available to investors today. That information is available publicly through Moderna media outlets and privately through word of mouth or via Moderna internal channels. However, regardless of the origin, that massive amount of Moderna data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Moderna news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Moderna relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Moderna's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Moderna alpha.

Moderna Largest EPS Surprises

Earnings surprises can significantly impact Moderna's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-26
2019-12-31-0.4215-0.370.051512 
2020-08-05
2020-06-30-0.363-0.310.05314 
2019-11-06
2019-09-30-0.4386-0.370.068615 
2019-03-06
2018-12-31-0.3505-0.44-0.089525 
2020-10-29
2020-09-30-0.3678-0.59-0.222260 
2021-02-25
2020-12-31-0.364-0.69-0.32689 
View All Earnings Estimates

Moderna Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Moderna Stock. Current markets are strongly bearish. About 90% of major world exchanges and indexes are down. See today's market update for more information.
Macroaxis News
28th of June 2022
Acquisition by Burton Paul of 6902 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
21st of June 2022
Acquisition by Burton Paul of 10990 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
14th of June 2022
Exercise or conversion by Hoge Stephen of 5000 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
9th of June 2022
Exercise or conversion by Klinger Shannon Thyme of 4554 shares of Moderna subject to Rule ...
at MacroaxisInsider 
Macroaxis News
3rd of June 2022
Exercise or conversion by Bancel Stephane of 40000 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
Macroaxis News
27th of May 2022
Exercise or conversion by Bancel Stephane of 40000 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
fool News
20th of May 2022
Moderna exotic insider transaction detected
at www.fool.com 
Macroaxis News
16th of May 2022
Exercise or conversion by Hoge Stephen of 10000 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 
fool News
11th of May 2022
Exercise or conversion by Andres Juan of 435 shares of Moderna subject to Rule 16b-3
at www.fool.com 
Macroaxis News
14th of April 2022
Exercise or conversion by Hoge Stephen of 10000 shares of Moderna subject to Rule 16b-3
at MacroaxisInsider 

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moderna Backtesting and Moderna Hype Analysis. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
56.8 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
MRNA
 Stock
  

USD 142.85  0.04  0.028%   

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Moderna and other traded companies coverage. We help investors stay connected with Moderna headlines for the 30th of June to make an informed investment decision based on correlating the impacts of news items on Moderna Stock performance. Please note that trading solely based on the Moderna hype is not for everyone as timely availability and quick action are needed to avoid losses. The current year Net Income Common Stock is expected to grow to about 13.2 B.
  
Refresh
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Moderna headlines in addition to utilizing other, more conventional financial analysis modules. Additionally, see Moderna Backtesting and Moderna Hype Analysis.
Moderna's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Moderna investors visualize upcoming and past events in order to time the market based on Moderna noise-free hype analysis.